摘要
Hypoxia is a well-established characteristic of prostate tumors and is now recognised as a major contributory factor to both tumor progression and increased resistance to therapy.One strategy to target hypoxic tumor cells is the development of hypoxia-activated prodrugs(HAPs),which are activated in low oxygen environments.Several HAPs have been developed but despite encouraging results from preclinical studies many of these have performed disappointingly in clinical trials.In the developing era of precision medicine,it is clear that more strategic deployment of these agents is required,based on reliable methods that can identify patients who will benefit from HAP treatment,either alone or in combination with other drugs.This review discusses the primary limitations of using HAPs to treat hypoxic tumors and explains how these challenges can be addressed.In particular,it emphasises the importance of tumor imaging and identification of reliable biomarkers for measuring hypoxia and monitoring cellular response to treatment in individual patients.Developing predictive assays for clinical use will be paramount in demonstrating the patient impact and effectiveness of HAPs for personalised medicine.
